Leyna Tran
Family Medicine · Montclair, CANPI 1851953335
Payments from drug & device makers
Across 186 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$504
- Novo Nordisk$468
- AbbVie$460
- Boehringer Ingelheim$452
- Ironwood Pharmaceuticals, Inc$297
- plus $962 from 16 others
What the payments were for
- Consulting fees$1754%
- Food & beverage$3,99194%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,122 |
| Amgen(2 entities) | 34 | $504 |
| Novo Nordisk | 20 | $468 |
| AbbVie | 23 | $460 |
| Boehringer Ingelheim | 17 | $452 |
| Ironwood Pharmaceuticals, Inc | 10 | $297 |
| Bayer | 5 | $106 |
| Lilly USA, LLC | 5 | $100 |
| Astellas Pharma US Inc | 1 | $100 |
| Sunovion Pharmaceuticals Inc. | 5 | $99 |
| Ardelyx, Inc. | 4 | $93 |
| GSK | 5 | $90 |
| Sumitomo Pharma America, Inc. | 4 | $85 |
| Vivus LLC | 3 | $58 |
| Amarin Pharma, Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Johnson & Johnson | 2 | $43 |
| Nestle Healthcare Nutrition Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,266 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 477 | $369,320 |
| FarxigaDapagliflozin Propanediol | 181 | $142,185 |
| VascepaIcosapent Ethyl | 301 | $117,253 |
| KerendiaFinerenone | 134 | $112,584 |
| LinzessLinaclotide | 148 | $109,930 |
| CreonLipase/Protease/Amylase | 79 | $106,384 |
| ProliaDenosumab | 43 | $70,809 |
| JanuviaSitagliptin Phosphate | 96 | $67,647 |
| OzempicSemaglutide | 61 | $64,422 |
| GemtesaVibegron | 101 | $63,006 |
| MyrbetriqMirabegron | 98 | $61,442 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $34,330 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $30,314 |
| RybelsusSemaglutide | 20 | $29,335 |
| Diclofenac Sodium | 101 | $24,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $452 | $391,722519 claims |
| AbbVieLinzess, Creon, Namzaric, Restasis | $460 | $253,808263 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $1,122 | $184,851241 claims |
| BayerKerendia | $106 | $112,584134 claims |
| Novo NordiskOzempic, Rybelsus | $468 | $93,75881 claims |
| AmgenProlia | $504 | $70,80943 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $85 | $63,006101 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $61,44298 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $90 | $55,20798 claims |
| Johnson & JohnsonXarelto | $43 | $13,87215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Montclair
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.